Xiaoming Zhang

Xiaoming Zhang

Auto-generated profile, based on publicly available information

Xiaoming Zhang

Department of Biostatistics, Epidemiology and Informatics; Center for Clinical Epidemiology and Biostatistics; Perelman School of Medicine of the University of Pennsylvania

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2023 in Annals of Internal Medicine
Verified
Journal Article
Closed access
AMAnthony N. Muiru
Anthony N. Muiru
JHJesse Y. Hsu
Jesse Y. Hsu
XZXiaoming Zhang
Xiaoming Zhang
LALawrence Appel
Lawrence Appel
JCJing Chen
Jing Chen
VSVallabh O. Shah
Vallabh O. Shah
Prior studies associating acute kidney injury (AKI) with more rapid subsequent loss of kidney function had methodological limitations, including inadequate control for differences between patients who had AKI and those who did not. To determine whether AKI is independently associated with subsequent kidney function trajectory among patients with chronic kidney disease (CKD). Multicenter prospective cohort study. United States. Patients with CKD (n = 3150). Hospitalized AKI was defined by a 50% or greater increase in inpatient serum creatinine (SCr) level from nadir to peak. Kidney function trajectory was assessed using estimated glomerular filtration rate (eGFR) based on SCr level (eGFRcr) or cystatin C level (eGFRcys) measured at annual study visits. During a median follow-up of 3.9 years, 433 participants had at least 1 AKI episode. Most episodes (92%) had stage 1 or 2 severity. There were decreases in eGFRcr (-2.30 [95% CI, -3.70 to -0.86] mL/min/1.73 m2) and eGFRcys (-3.61 [CI, -6.39 to -0.82] mL/min/1.73 m2) after AKI. However, in fully adjusted models, the decreases were attenuated to -0.38 (CI, -1.35 to 0.59) mL/min/1.73 m2 for eGFRcr and -0.15 (CI, -2.16 to 1.86) mL/min/1.73 m2 for eGFRcys, and the CI bounds included the possibility of no effect. Estimates of changes in eGFR slope after AKI determined by either SCr level (0.04 [CI, -0.30 to 0.38] mL/min/1.73 m2 per year) or cystatin C level (-0.56 [CI, -1.28 to 0.17] mL/min/1.73 m2 per year) also had CI bounds that included the possibility of no effect. Few cases of severe AKI, no adjudication of AKI cause, and lack of information about nephrotoxic exposures after hospital discharge. After pre-AKI eGFR, proteinuria, and other covariables were accounted for, the association between mild to moderate AKI and worsening subsequent kidney function in patients with CKD was small. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.

4 June 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
SSSarah J. Schrauben
Sarah J. Schrauben
XZXiaoming Zhang
Xiaoming Zhang
DXDawei Xie
Dawei Xie
SCSteven Coca
Steven Coca
JGJason H. Greenberg
Jason H. Greenberg
OIOn behalf of the CKD Biomarkers Consortium and the CRIC investigators
On behalf of the CKD Biomarkers Consortium and the CRIC investigators
Key Points: Higher urine levels of kidney injury molecule-1 and monocyte chemoattractant protein-1 were associated with higher risk of CKD progression. Higher urine levels of EGF were associated with lower risk of CKD progression. Urine kidney injury molecule-1, monocyte chemoattractant protein-1, and EGF may noninvasively assess tubule and interstitial health in diabetes and identify those at higher risk of CKD progression. Background: Urine biomarkers of kidney tubular health and inflammation may provide a noninvasive way to identify individuals with diabetes at higher risk for CKD progression given that the extent of tubulointerstitial pathology is related to progression of diabetic kidney disease. Methods: We performed a case-cohort study among 898 participants in the Chronic Renal Insufficiency Cohort with diabetes and eGFR <60 ml/min per 1.73 m2. Of these individuals, the subcohort (N=599) was randomly selected from participants with urine samples available 1 year or less after enrollment to assay for urine proteins. Cases were participants who developed CKD progression (incident ESKD, or eGFR decline of 40% or greater from baseline). The median follow-up was 7.35 years. We studied urinary biomarkers of tubulointerstitial inflammation (monocyte chemoattractant protein-1 [MCP-1]), proximal tubular injury (kidney injury molecule-1 [KIM-1]), tubular resorptive capacity (α1-microglobulin), and tubular synthetic capacity (EGF and uromodulin). Weighted Cox regression models related urine biomarkers, standardized to urine creatinine (Cr), with CKD progression and were adjusted for CKD risk factors, including eGFR, and urine albumin-to-creatinine ratio. Results: In fully adjusted models, higher urine KIM-1/Cr was associated with higher risk of CKD progression (hazard ratio [HR], 1.16 per two-fold higher; 95% confidence interval [CI], 1.05 to 1.29) and the highest quartiles of urine KIM-1/Cr and urine MCP-1/Cr, compared with the lowest quartile, were associated with higher risk of CKD progression (HR, 1.71; 95% CI, 1.15 to 2.55, and HR, 1.65; 95% CI, 1.10 to 2.47, respectively). Higher urine levels of EGF/Cr were associated with lower risk of CKD progression (HR, 0.81 per two-fold higher; 95% CI, 0.71 to 0.93), and the highest quartile of urine EGF/Cr, compared with lowest, associated with less CKD progression (HR, 0.57; 95% CI, 0.40 to 0.81). Conclusions: Urine MCP-1, KIM-1, and EGF may provide noninvasive ways to assess tubule and interstitial disease in diabetes and identify those at higher risk of CKD progression.

28 April 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
IMIan E. McCoy
Ian E. McCoy
JHJesse Y. Hsu
Jesse Y. Hsu
XZXiaoming Zhang
Xiaoming Zhang
CDClarissa J. Diamantidis
Clarissa J. Diamantidis
JTJonathan Taliercio
Jonathan Taliercio
OIon behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
Background: Patients hospitalized with AKI have higher subsequent risks of heart failure, atherosclerotic cardiovascular events, and mortality than their counterparts without AKI, but these higher risks may be due to differences in prehospitalization patient characteristics, including the baseline level of estimated glomerular filtration rate (eGFR), the rate of prior eGFR decline, and the proteinuria level, rather than AKI itself. Methods: Among 2177 adult participants in the Chronic Renal Insufficiency Cohort study who were hospitalized in 2013–2019, we compared subsequent risks of heart failure, atherosclerotic cardiovascular events, and mortality between those with serum creatinine–based AKI (495 patients) and those without AKI (1682 patients). We report both crude associations and associations sequentially adjusted for prehospitalization characteristics including eGFR, eGFR slope, and urine protein-creatinine ratio (UPCR). Results: Compared with patients hospitalized without AKI, those with hospitalized AKI had lower eGFR prehospitalization (42 versus 49 ml/min per 1.73 m2), faster chronic loss of eGFR prehospitalization (−0.84 versus −0.51 ml/min per 1.73 m2 per year), and more proteinuria prehospitalization (UPCR 0.28 versus 0.16 g/g); they also had higher prehospitalization systolic BP (130 versus 127 mm Hg; P < 0.01 for all comparisons). Adjustment for prehospitalization patient characteristics attenuated associations between AKI and all three outcomes, but AKI remained an independent risk factor. Attenuation of risk was similar after adjustment for absolute eGFR, eGFR slope, or proteinuria, individually or in combination. Conclusions: Prehospitalization variables including eGFR, eGFR slope, and proteinuria confounded associations between AKI and adverse cardiovascular outcomes, but these associations remained significant after adjusting for prehospitalization variables.

11 March 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
IMIan E. McCoy
Ian E. McCoy
AGAlan S. Go
Alan S. Go
JHJesse Y. Hsu
Jesse Y. Hsu
XZXiaoming Zhang
Xiaoming Zhang
AMAnthony N. Muiru
Anthony N. Muiru
CHChi-Yuan Hsu
Chi-Yuan Hsu
Key Points: Critical illness is known to acutely decrease eGFRdiff (estimation of GFR by cystatin C−estimation of GFR from serum creatinine [eGFRCr]), presumably because of loss of muscle mass falsely elevating eGFRCr. It is unknown whether this eGFRdiff effect occurs in all-cause hospitalizations and whether the effect persists after hospitalization. More hospitalization was associated with larger decreases in estimation of GFR by cystatin C compared with eGFRCr on measurements months after hospital discharge. Background: Cystatin C has entered mainstream clinical care as a measure of kidney function, joining serum creatinine, which has been used for almost a century. However, many physicians notice that estimation of GFR from serum creatinine (eGFRCr) and estimation of GFR by cystatin C (eGFRCys) values can differ considerably. Hospitalization with critical illness is known to acutely decrease eGFRdiff (eGFRCys−eGFRCr). However, whether this effect occurs in all-cause hospitalizations and persists after hospitalization is unknown. Methods: Among 5599 adult participants in the Chronic Renal Insufficiency Cohort study with serum creatinine and cystatin C measurements, we estimated the association of six categories of total days of hospitalization between annual study visits (never hospitalized, hospitalized <7, 7 to <14, 14 to <28, 28 to <42, and ≥42 days) and changes in eGFRCr, eGFRCys, and eGFRdiff between those study visits. Results: Compared with no hospitalization between study visits, increasing days of hospitalization were associated with decreases in eGFRCys ( e.g ., −3.30 [95% confidence interval, −5.48 to −1.13] ml/min per 1.73 m 2 for ≥42 days of hospitalization, test for trend P < 0.001), while eGFRCr remained relatively stable ( e.g ., −1.12 [−2.77 to 0.53] ml/min per 1.73 m 2 for ≥42 days of hospitalization, test for trend P = 0.21). The differential effect resulted in eGFRdiff becoming progressively more negative with more total days of hospitalization (test for trend P < 0.001). Conclusions: Prolonged or repeated hospitalization was associated with larger decreases in eGFRCys compared with eGFRCr on measurements months after hospital discharge.

17 February 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
ARAna C. Ricardo
Ana C. Ricardo
SPSunho Park
Sunho Park
ECEunice Carmona-Powell
Eunice Carmona-Powell
CLClaire Larkin
Claire Larkin
AQArabela Quiroga
Arabela Quiroga
TIthe CRIC Study Investigators
the CRIC Study Investigators
Key Points: The Beck Depression Inventory is a valid instrument to screen for depressive symptoms in Hispanic adults with CKD. Using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Disorders as the gold standard, a Beck Depression Inventory of ≥16 was found to be the optimal screening cutoff in Hispanic adults with nondialysis CKD or ESKD. Background: Depression is common in patients with CKD. Self-report scales, including the Beck Depression Inventory (BDI), have been evaluated in non-Hispanic adults with CKD for screening of depressive symptoms. However, the BDI has not been validated in Hispanic adults with CKD. Methods: We investigated the screening characteristics of the BDI in 248 Hispanic adults (164 with CKD and 84 with ESKD) enrolled in the Hispanic Chronic Renal Insufficiency Cohort Study. Two trained study personnel administered the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Disorders, which served as the gold-standard measure for the diagnosis of major depression. Results: Among the 164 participants with CKD, the mean (SD) age was 61 (0.8) years, 37% were female, 77% spoke primarily Spanish, mean (SD) eGFR was 37 (1.3) ml/min per 1.73 m2, and median (interquartile range) proteinuria was 0.4 (0.1–2.0) g/g. Using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Disorders, 24 (15%) were classified as having current major depressive disorder. The best cutoff BDI score to identify current major depression disorder on the basis of the receiver-operating characteristic curve was 16. Sensitivity was 88%, specificity was 84%, positive predictive value was 49%, and negative predictive value was 98%. Similar results were found in participants with ESKD. Conclusions: A BDI score of ≥16 was sensitive and specific for identifying major depression in US Hispanic adults with CKD and ESKD, which is a higher cutoff than reported for non-Hispanic patients with CKD. These differences in psychometric properties should be considered in future research and clinical practice.

20 November 2025 in Kidney360
Verified
Journal Article
Open access
YKYuenting Diana Kwong
Yuenting Diana Kwong
KLKathleen D. Liu
Kathleen D. Liu
IMIan E. McCoy
Ian E. McCoy
AMAnthony N. Muiru
Anthony N. Muiru
MWMatthew R. Weir
Matthew R. Weir
CHChi-Yuan Hsu
Chi-Yuan Hsu
Key Points: Quantifying albuminuria 3 months after AKI predicts future risk of kidney disease progression but is often not completed. In a cohort of 554 patients with CKD, urine protein-to-creatinine ratio measured within 1 year after AKI had robust prognostic value. Testing of total proteinuria beyond 3 months after AKI among patients with CKD identified those at risk of kidney disease progression. Background: Expert consensus recommends quantifying albuminuria 3 months after hospitalized AKI to identify patients at risk for kidney disease progression, but testing is often not completed in clinical practice. We evaluated the utility of testing total proteinuria (which is less expensive than albuminuria) and on a less rigid time schedule after AKI to facilitate its adoption into clinical practice. Methods: Prospective multicenter cohort study of patients with CKD who were hospitalized with AKI between 2013 and 2021. Urine protein-to-creatinine ratio (PCR) was assessed per research protocol within 1 year of hospital discharge. Cox proportional hazard models were applied with a focus on C-statistics as the primary metric regarding post-AKI PCR's ability to discriminate risk of kidney disease progression as defined by halving of eGFR or ESKD. Results: Five hundred and fifty-four Chronic Renal Insufficiency Cohort participants (43% female, 51% non-Hispanic Black, mean eGFR 43 ml/min per 1.73 m 2 ) had PCR measurements within a year of AKI hospital discharge (82% stage 1 AKI). The median PCR, obtained 147 median (interquartile range, 79-233) days after AKI, was 0.36 mg/g (interquartile range, 0.12–1.37 mg/g). Over the mean follow-up of 2.6 years, 124 participants had kidney disease progression. Higher post-AKI PCR was associated with increased risk of kidney disease progression (hazard ratio, 2.99 for each doubling of proteinuria; 95% confidence interval, 2.54 to 3.52; C-statistic, 0.80). An adjusted model including demographic and clinical risk factors had high discrimination for kidney disease progression (C-statistic, 0.86). Renin-angiotensin system inhibitors use decreased after AKI, especially among patients with higher AKI stage and lower eGFR. Conclusions: Proteinuria evaluation by PCR within 1 year after AKI hospital discharge may be a feasible and flexible option for risk-stratifying survivors at higher risk of subsequent kidney function loss. We also identified opportunities to optimize management of proteinuria after AKI.